LIXTE Biotechnology Holdings, Inc. has announced recent scientific developments regarding its drug candidates, including inhibitors targeting protein phosphatase 2A.
4 reports, 2 independent
Updated Sep 5
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 5
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
LIXTE Biotechnology Holdings, Inc. has announced recent scientific developments regarding its drug candidates, including inhibitors targeting protein phosphatase 2A.
How it developed
Newest first. Tap a step to see who reported it.- A study led by Amir Jazaeri validated the efficacy of LIXTE's compound LB100.Sub-event
- LIXTE's compound is being studied in collaboration with Roche and GlaxoSmithKline.Sub-event
LIXTE develops inhibitors targeting protein phosphatase 2A and demonstrates efficacy of LB-100 in cancer treatment.1 source
LB-100 established as a first-in-class PP2A inhibitor for cancer treatment.1 source
LIXTE is testing LB-100 in Phase 1B/2 to overcome platinum resistance for various cancers.1 source
Coverage
Newest first; wire copies grouped- Newsfile24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor Unlocking a New Era in Cancer Treatment Denver, Colorado--(Newsfile Corp. - September 5, 2025) - 247marketnews.com, a pion
- GlobeNewswire24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy New Peer-Reviewed Publication Highlights Landmark Meeting Co-Sponsored by LIXTE
- GlobeNewswire24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100 LIXTE Biotechnology’s LB-100 Featured in Nature Reviews Cancer Editorial: A Game-Changer
- GlobeNewswire24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025 Breakthrough Epigenetic Modulator LB-100 Targets Ovarian Clear Cell Ca